Podcast
Medical News Podcast
Hosted by PeerDirect · EN
The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.
52episodes
Episodes
Newest firstAll episodes
How Long Is Too Long? Maintenance Therapy for Patients With Lupus Nephritis
5d ago00:09:12Tap to summarizeDrs. McMahon and Kalunian discuss how the latest lupus nephritis guidelines from the American College of Rheumatology and European Alliance of Associations for Rheumatology are shifting care from short-term, reactive treatment to longer-term, continuous maintenance—often 3 to 5 years or more—to better prevent kidney flares and preserve renal function. They highlight emerging data on biologic-based triple therapy (including belimumab); the importance of biomarkers and repeat biopsies; and the growing push toward personalized, sometimes indefinite, therapy for high‑risk patients.
Transcribe →Facial Pain, Migraine, and the Trigeminal System
6d ago00:12:24Tap to summarizeDrs. Chandwani and Kuruvilla explain that migraine and facial pain often share trigeminal system mechanisms, leading to frequent misdiagnosis as dental, musculoskeletal, or sinus problems, possibly resulting in unnecessary procedures. The speakers emphasize CGRP-targeted therapies, careful mechanism-based diagnosis, and multidisciplinary collaboration across neurology, orofacial pain, physical therapy, and behavioral health to improve outcomes for patients with complex facial pain and migraine presentations.
Transcribe →CLL at ASH 2025: Time Limited Triplet, Timing of Anti-CD20 Therapy, and GAIA/CLL13
1w ago00:15:27Tap to summarizeDrs. Wierda and O’Brien discuss new combination treatments for CLL that achieve exceptionally high rates of undetectable disease, especially with triplet regimens. They also show that venetoclax-based retreatment works very well, supporting a move away from chemoimmunotherapy.
Transcribe →2026 Macula Society Meeting: New Developments for Retinal Diseases
1w ago00:11:30Tap to summarizeDrs. Yiu and Emami continue their wrap-up of the highlights from the 49th Annual Macula Society Meeting, focusing on new developments in imaging technologies, AI, and drug delivery for retinal diseases. They also touch on emerging basic science topics like the gut microbiome and metabolomics, and how these may support more personalized, systems-level approaches to eye disease.
Transcribe →HER2+ Genitourinary Cancers: Targeted Therapy Highlights From ESMO 2025
2w ago00:14:00Tap to summarizeDrs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.
Transcribe →Could a new oral pan-RAS inhibitor finally change the outlook for KRAS-mutated pancreatic cancer?
2w ago00:05:20Tap to summarizeThis episode of the PeerDirect Medical News Podcast explores promising new data on the oral pan-RAS inhibitor daraxonrasib in KRAS-mutated pancreatic cancer, a randomized stroke trial evaluating adjunctive tirofiban after tenecteplase, and AI-driven breast cancer risk prediction models that may outperform breast density alone. Together, these studies highlight emerging advances in targeted oncology, acute stroke management, and precision screening technologies that could influence future clinical practice.
Transcribe →ATTR-CM in 2026: Stabilizers vs Silencers – How Are You Choosing?
2w ago00:12:15Tap to summarizeDrs. Sarswat and Dasgupta discuss contemporary decision-making in treating transthyretin amyloidosis, comparing oral stabilizers with subcutaneous silencers and emphasizing earlier diagnosis, phenotype-driven therapy, and individual patient preferences. They highlight how neuropathy and autonomic dysfunction influence choice of mechanism, review practical considerations such as side-effect profiles, dosing logistics, and drug–drug interactions, and briefly touch on emerging approaches like amyloid-removing and gene-targeted therapies.
Transcribe →Highlights From ISC 2026: The CREST-2 Cognitive Substudy and Oral Health and Stroke Risk
4w ago00:09:04Tap to summarizeDrs. Sanossian and Saver highlight emerging evidence that routine dental care and oral hygiene may function as actionable, modifiable contributors to stroke prevention beyond traditional vascular risk factors. They also review CREST-2 data showing that carotid revascularization in asymptomatic high-grade carotid stenosis reduces stroke risk, but does not appear to confer additional cognitive benefit over intensive medical therapy alone.
Transcribe →AI, Machine Learning, and HRCT in ILD: Fibrosis Quantification
4w ago00:13:26Tap to summarizeDrs. Swigris and Humphries discuss how data-driven texture analysis (DTA) on HRCT enables precise, objective quantification of fibrotic burden in ILD, overcoming the limitations of semi-quantitative visual scoring and blunt physiologic measures. They further describe a complementary AI-based classifier that predicts histologic usual interstitial pneumonia (UIP) patterns from CT, enhancing prognostication and potentially reducing the need for surgical lung biopsy.
Transcribe →HER2 in Genitourinary Cancers: Clinical Relevance and Real-World Testing Considerations
May 100:11:14Tap to summarizeDrs. Mantia and Berg discuss HER2 as a biomarker in genitourinary cancers, focusing on testing strategies, prevalence, and the clinical implications of HER2 expression and ERBB2 mutations for patient management. They also review new data from ESMO 2025, highlighting the DISTINCT-1 trial and a HER2-targeted approach for high-risk upper tract genitourinary carcinoma.
Transcribe →